Cancer Immunotherapy Market Estimated to be Worth USD 153.03 Billion by 2027 | CAGR of 10.1%: Emergen Research – PR Newswire UK

- The increasing prevalence of cancer and rising R&D activities in the cancer immunotherapy field is driving the demand for the market.

- Market Size USD 78.04 billion in 2019, Market Growth - CAGR of 10.1%, Market trends Growing health awareness and effectiveness of treatment

VANCOUVER, B.C, Sept. 17, 2020 /PRNewswire/ --The globalCancer Immunotherapy Marketis expected to reach USD 153.03 Billion by 2027, according to a new report by Emergen Research. The cancer immunotherapy market is growing at a substantial pace owing to the growing acceptance and inclination of the patients towards the newly invented advanced treatments over the conventional ones. In order to substantialize the severe and chronic diseases like cancer, every year, the cancer research centers invest a handful of the amount in their R&D, which fuels up the market growth by a large margin.

Key factors responsible for driving the growth of the cancer immunotherapy market include technological advancements in therapy, rising incidences of cancer, increasing R&D activities for the treatment of cancer, and the improving effectiveness of cancer immunotherapy for the treatment of a wide range of diseases, such as lung cancer, breast cancer, and skin cancer, among others. Factors that could significantly limit market growth is the high price of the slow and long-term procedure, expensive treatment and R&D, and stringent government regulations. Moreover, product approvals and high cost of treatment are expected to act as a restraining factor on the growth of the global market in the near future.

Request free sample of this research report at: https://www.emergenresearch.com/request-sample/63

Key Highlights From The Report

To get leading market solutions, visit the link below:https://www.emergenresearch.com/industry-report/cancer-immunotherapy-market

For the purpose of this report, Emergen Research has segmented the Global Cancer Immunotherapy Market on the basis of technology, application, end-use, and region:

Technology Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

End-Use Outlook (Revenue, USD Billion; 2017-2027)

Regional Outlook (Revenue, USD Billion; 2017-2027)

Find more similar research insights by Emergen Research:

Hearing Aids MarketBy Type (Behind-the-ear- Hearing Aids, Receiver in-the-ear Hearing Aids, In-the-ear Hearing Aids, Canal Hearing Aids), By Hearing Loss, By Application (Adults, Pediatrics), By Distribution Channel, Forecasts to 2027

Continuous Glucose Monitoring System MarketBy Component (Insulin Pumps, Transmitters & Receivers, Sensors), By End Use (Hospitals, Homecare Settings, Others), and Regions Forecasts to 2027

Injectable Drug Delivery MarketBy Product Type (Formulations, Devices), By Therapeutic Application (Hormonal disorders, Autoimmune disorders, Oncology), By End-User (Homecare settings, Hospitals & Clinics), Forecasts to 2027

Molecular Diagnostics MarketBy Product (Reagents, Instruments), By Technology (DNA Sequencing and NGS, PCR, In Situ Hybridization), By Application (Oncology, Infectious Diseases), By End-User (Central Laboratories, Hospitals), Forecasts to 2027

Teleradiology Services MarketBy Imaging Technique (MRI, CT, X-Rays, Ultrasound, Mammography), By End-Users (Diagnostic Centers, Hospitals & Clinics), By Products and Services (Software, Hardware, Teleradiology services), Forecasts to 2027

Pharmacogenomics MarketBy Offering (Hardware, Software, Services), By Technology (Machine Learning, Natural Language Processing (NLP), Context-Aware Computing), By End-User Industry (Healthcare, Manufacturing, Agriculture, Automotive), and By Region, Forecasts to 2027

About Emergen Research

At Emergen Research, we believe in advancing with technology. We are a growing market research and strategy consulting company with an exhaustive knowledge base of cutting-edge and potentially market-disrupting technologies that are predicted to become more prevalent in the coming decade.

With market-leading insights and an in-depth understanding of leading and niche technologies, our solutions address the most pertinent questions for your business needs. A major technological shift has been witnessed towards creating a 'Circular Economy,' fuelled by factors, such as the increased adoption of bio-based materials, along with other methods for achieving carbon neutrality. We are conversant in technologies, viz., Artificial Intelligence (AI), Augmented Reality (AR), Virtual Reality (VR), Robotic Process Automation (RPA), Smart Manufacturing, Internet of Things (IoT), Big Data Analytics, Machine learning, Nanotechnology, Edge Computing, Blockchain Technology, Cloud Computing, Vehicle Electrification, Advanced Maintenance Analytics, and Predictive Maintenance, among other prevalent and emergent technologies.

Contact Us:

Eric LeeCorporate Sales SpecialistEmergen Research | Web: https://www.emergenresearch.comE-mail: sales@emergenresearch.com

Read full Press Release at : https://www.emergenresearch.com/press-release/global-cancer-immunotherapy-market

Logo: https://mma.prnewswire.com/media/1252126/Emergen_Research_Logo.jpg

SOURCE Emergen Research

Read more:
Cancer Immunotherapy Market Estimated to be Worth USD 153.03 Billion by 2027 | CAGR of 10.1%: Emergen Research - PR Newswire UK

Pharmacogenomics Automotive Grease Market to Witness Growth Acceleration During 2020-2027 – Verdant News

The research study on Pharmacogenomics Market added byReportspediapresents an extensive analysis of current Pharmacogenomics Market size, drivers, trends, opportunities, challenges, as well as key market segments. In continuation of this data, the Pharmacogenomics Market report covers various marketing strategies followed by key players and distributors.

During the estimated period, the report also mentions the predictable CAGR of the global Pharmacogenomics Market. The report provides readers with accurate past statistics and predictions of the future. In order to get an in-depth overview of Global Pharmacogenomics Market is valued at USD XX million in 2020 and is predictable to reach USD XX million by the end of 2027, growing at a CAGR of XX% between 2020 and 2027.

Free Sample PDF Copy Here @:

https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#request_sample

Top Key Players:

Bayer AGBecton, Dickinson and CompanyAffymetrix, Inc.F. Hoffmann-La Roche AGQIAGENAbbott Laboratories, Inc.Bio-Rad Laboratories, Inc.Thermo Fisher Scientific Inc.Illumina, Inc.AstraZeneca PLC

The report on Pharmacogenomics market is also provided, details of the company enclosed, SWOT analysis, and PESTEL, Porters five forces, and product life cycle. In the start, the report offers a basic introduction of the Pharmacogenomics industry containing its definition, applications and production technique. Then, the report illustrates the international key Pharmacogenomics industry players in detail.

Geographical Analysis of Pharmacogenomics Market:

Ask For [emailprotected]:

https://www.reportspedia.com/discount_inquiry/discount/58762

Pharmacogenomics Market Segmentation:

Pharmacogenomics Market Segmentation By Type:

DNA SequencingMicroarray, Polymerase Chain ReactionElectrophoresisMass SpectrometryOthers

Pharmacogenomics Market Segmentation By Application:

Drug DiscoveryTailored TreatmentOncologyPain ManagementOther Therapeutic Applications

Global Pharmacogenomics Market: Competitive Analysis

This section of the report identifies a variety of key manufacturers in the market. It helps the reader know the strategies and collaboration that players are focus on combat competition in the market. The wide-ranging report provides a major microscopic look at the market. The reader can discover the footprints of the manufacturers by knowing about the global revenue of manufacturers and sales by manufacturers during the forecast period of 2020 to 2027.

In this Pharmacogenomics market study, the following years are considered to project the market footprint:

History Year:2014 2018

Base Year:2018

Estimated Year:2019

Forecast Year:2020 2027

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected]:

https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#inquiry_before_buying

Pharmacogenomics market research addresses the following queries:

Main points of the table of contents:

Chapter One: Report Overview

Chapter Two: Trends in Global Growth

Chapter Three: Market Share of Major Players

Chapter Four: Distribution by Type and Application

Chapter Five: United States

Chapter Six: Europe

Chapter Seven: China

Chapter Eight: Japan

Chapter Nine: Southeast Asia

Chapter Ten: India

Chapter Eleven: Central and South America

Chapter Twelve: Profiles of International Players

Chapter Thirteen: Market Forecast 2020-2027

Chapter Fourteen: Analyst Views / Findings

Get Full Table of [emailprotected]:

https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#table_of_contents

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, and Asia.

Read the original here:
Pharmacogenomics Automotive Grease Market to Witness Growth Acceleration During 2020-2027 - Verdant News

Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market and Forecast Analyzed in a New Research Report – The Daily Chronicle

Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The report provides both quantitative and qualitative information of global Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market was valued at USD _ million/billion.

This research report based on Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market that includes numerous regions. Likewise, the report also expands on intricate details pertaining to contributions by key players, demand and supply analysis as well as market share growth of the Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) industry.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2795996&source=atm

Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Overview:

The Research projects that the Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market size will grow from in 2018 to by 2024, at an estimated CAGR of XX%. The base year considered for the study is 2018, and the market size is projected from 2018 to 2024.

Leading manufacturers of Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market:

segment by Type, the product can be split intoPCRIn-situ HybridizationImmunohistochemistrySequencingOthers

Market segment by Application, split intoOncologyNeurological DisordersCardiovascular DiseaseImmunological DisordersOthers

Based on regional and country-level analysis, the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market has been segmented as follows:North AmericaUnited StatesCanadaEuropeGermanyFranceU.K.ItalyRussiaNordicRest of EuropeAsia-PacificChinaJapanSouth KoreaSoutheast AsiaIndiaAustraliaRest of Asia-PacificLatin AmericaMexicoBrazilMiddle East & AfricaTurkeySaudi ArabiaUAERest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.The key players covered in this studyQiagen NVGE HealthcareAgilent TechnologiesF Hoffman La RocheFoundation MedicineThermo Fisher Scientific Inc.Leica Biosystems Nussloch GmBHPfizer

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2795996&source=atm

Some important highlights from the report include:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2795996&licType=S&source=atm

The Questions Answered by Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report:

And Many More.

Read more here:
Japan Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market and Forecast Analyzed in a New Research Report - The Daily Chronicle

Scientists are working on vaccines that spread like a disease. What could possibly go wrong? – Bulletin of the Atomic Scientists

A worker conducts testing during the 2014 Ebola outbreak in Liberia. Credit: John Saindon/Centers for Disease Control and Prevention. CC BY 2.0.

Once a COVID-19 vaccine is approved for public use, officials around the world will face the monumental challenge of vaccinating billions of people, a logistical operation rife with thorny ethical questions. What if instead of orchestrating complicated and resource-intensive campaigns to vaccinate humans against emerging infectious diseases like COVID-19, we could instead stop the zoonotic diseases that sometimes leap from animals to people at their source? A small, but growing number of scientists think its possible to exploit the self-propagating properties of viruses and use them to spread immunity instead of disease. Can we beat viruses like SARS-CoV-2, the novel coronavirus, at their own game?

A virus that confers immunity throughout an animal population as it spreads in the wild could theoretically stop a zoonotic spillover event from happening, snuffing out the spark that could ignite the next pandemic. If the wild rats that host the deadly Lassa virus, for example, are vaccinated, the risks of a future outbreak among humans could be reduced. For at least 20 years, scientists have been experimenting with such self-spreading vaccines, work that continues to this day, and which has gained the attention of the US military.

For obvious reasons, public and scientific interest in vaccines is incredibly high, including in self-spreading vaccines, as they could be effective against zoonotic threats. The biologists Scott Nuismer and James Bull generated fresh media attention to self-spreading vaccines over the summer after publishing an article in the journal Nature Ecology & Evolution. But the subsequent reporting on the topic gives short shrift to the potentially significant downsides to releasing self-spreading vaccines into the environment.

Self-spreading vaccines could indeed entail serious risks, and the prospect of using them raises challenging questions.

Who decides, for instance, where and when a vaccine should be released? Once released, scientists will no longer be in control of the virus. It could mutate, as viruses naturally do. It may jump species. It will cross borders. There will be unexpected outcomes and unintended consequences. There always are.

While it may turn out to be technically feasible to fight emerging infectious diseases like COVID-19, AIDS, Ebola, and Zika with self-spreading viruses, and while the benefits may be significant, how does one weigh those benefits against what may be even greater risks?

How they work. Self-spreading vaccines are essentially genetically engineered viruses designed to move through populations in the same way as infectious diseases, but rather than causing disease, they confer protection. Built on the chassis of a benign virus, the vaccines have genetic material from a pathogen added to them that stimulates the creation of antibodies or white blood cells in infected hosts.

These vaccines could be particularly useful, some scientists say, for wildlife populations where direct vaccination is difficult due to issues like inaccessible habitats, poor infrastructure, high costs, or lack of resources. The idea, essentially, is to vaccinate a small proportion of a population through direct inoculation. These so-called founders will then passively spread the vaccine to other animals they encounter either by touch, sex, nursing, or breathing the same air. Gradually, these interactions could build up population-level immunity.

Self-spreading vaccines have some of their roots in efforts to reduce pest populations. Australian researchers described a virally spread immunocontraception, which hijacked the immune systems of infected animalsin this case a non-native mouse species in Australiaand prevented them from fertilizing offspring. The earliest self-spreading vaccine efforts targeted two highly lethal infectious diseases in the European rabbit population (myxoma virus and rabbit hemorrhagic disease virus). In 2001, Spanish researchers field-tested a vaccine in a wild rabbit population living on Isla del Aire, a small Spanish island just off Menorca. The vaccine spread to more than half the 300 rabbits on the island, and the trial was deemed a success.

In 2015, another team of researchers speculated on the development of a self-spreading vaccine for the Ebola virus that could be used on wild great apes like chimpanzees. Since then, scientists have come to see a wide array of animalsfrom wildlife such as bats, birds, and foxes to domesticated animals like dogs, pigs, and sheepas amenable to self-spreading vaccines.

So far, researchers have not developed experimental self-spreading vaccines for humans; there is no clear evidence that anybody is actively working on the technology. Nuismer and Bull argue, rather, that self-spreading vaccines present a revolutionary approach to control emerging infectious diseases before they even spill over from animals into the human population.

Zoonotic spillover is certainly a pressing problem; alongside SARS-CoV-2, HIV, Ebola virus, and the Zika virus, there are over a thousand other new viruses with zoonotic potential that have been detected in wild animals over the last decade. Prevention is better than a cure, Nuismer and Bull say in a New Scientist article. In their Nature Ecology & Evolution article, they claim they are poised to begin developing self-disseminating vaccines to target a wide range of human pathogens in animals.

Outside of an experiment, scientists would face massive technical and practical hurdles in identifying the most appropriate targets for intervention and ensuring immunity is maintained in the wildlife populations. Despite these substantial challenges, the potential security implications of self-spreading vaccines are even more serious.

The principal security concern is that of dual-use. In essence, this means that the same research that is used to develop self-spreading vaccines to prevent disease, could also be used to deliberately cause harm. You could, for instance, engineer triggers into a virus that cause immune system failures in infected people or animals, a bit like HIV does naturally. Or you could create triggers in a virus that cause a harmful autoimmune response, where the body starts attacking its own healthy cells and tissues.

The bioweapon question. While researchers may intend to make self-spreading vaccines, others could repurpose their science and develop biological weapons. Such a self-spreading weapon may prove uncontrollable and irreversible.

We dont have to dig very deep for a historical example of weaponized biology. As the apartheid-era South African biowarfare program shows, social, political, and scientific pressures can lead to the misuse of biological innovation.

Codenamed Project Coast, South Africas program was primarily focused on covert assassination weapons for use against individuals deemed a threat to the racist apartheid government. In addition to producing contraptions to inject poisons, Project Coast researchers developed techniques to lace sugar cubes with salmonella and cigarettes with Bacillus anthracis.

While there have been many biowarfare programs, including several that were far more elaborate and sophisticated, the South African program is particularly relevant in thinking through malicious uses of self-spreading vaccines. One of Project Coasts research projects aimed at developing a human anti-fertility vaccine.

The idea took hold during a time of widespread concern over worldwide population explosion. Schalk Van Rensburg, who oversaw fertility-related work at a Project Coast laboratory, told South Africas post-apartheid Truth and Reconciliation Commission, a forum for examining the sordid history of the era and laying the foundation for future peace and tolerance, that he thought the project was in line with the World Health Organizations attempts to curb rising global birth rates. He believed it could bring his lab international acclaim and funding. According to Van Rensburg, Wouter Basson, the director of the biowarfare program, said the military needed an anti-fertility vaccine so that female soldiers would not fall pregnant.

While some of the scientists involved in the project denied awareness of ulterior intentions or even that their fertility work was part of a military endeavor, Van Rensburg and Daniel Goosen, a lab director, told the Truth and Reconciliation Commission that the real intention behind the project was to selectively administer the contraceptive in secret to unwitting Black South African women.

In the end, the anti-fertility vaccine was not produced before Project Coast was officially closed down in 1995, 12 years after it was initiated. An early version was tested in baboons, but never in humans. South Africa isnt the only country to try and forcibly sterilize parts of its population. European countries, including Sweden and Switzerland, sterilized members of the Roma minority in the early half of the 20th century and some, like Slovakia, continued even beyond that. More recently, analysts have alleged that the Chinese government is sterilizing women in Xinjiang, a province with a large population of Uighur Muslims.

It doesnt take a massive leap of the imagination to see how the aims of South Africas anti-fertility vaccine project would have benefited from research into self-spreading vaccines, particularly if you combine it with current developments in pharmacogenomics, drug development, and personalized medicine. Taken together, these strands of research could help enable ultra-targeted biological warfare.

An expanding potential for abuse. The Biological Weapons Convention, the treaty that bans biological weapons, is nearly 50 years old. Negotiated and agreed to in the depths of the Cold War, the convention suffers from outdated modes of operation. There are also significant compliance assessment challenges. The convention certainly didnt stop South Africa from pursuing Project Coast in the early 1980s.

Self-spreading vaccine research is a small but growing field. At the moment, about 10 institutions are doing significant work in the area. These laboratories are primarily located in the United States, but some are in Europe and Australia, as well. As the field expands, so does the potential for abuse.

So far research has primarily been bankrolled by US government science and health funders like the National Science Foundation, the National Institutes of Health, and the Department of Health and Human Services. Private organizations like the Gates Foundation and academic institutions have also financed projects. Recently, the Defense Advanced Research Projects Agency (DARPA), sometimes thought of as the US militarys research and development wing, has gotten involved in the research. The University of California, Davis, for example, is working on a DARPA administered project called Prediction of Spillover Potential and Interventional En Masse Animal Vaccination to Prevent Emerging Pathogen Threats in Current and Future Zones of US Military Operation. According to a pamphlet, the project is creating the worlds first prototype of a self-disseminating vaccine designed to induce a high level of herd immunity (wildlife population level protection) against Lassa virus and Ebola.

Military investment in biological innovation for defensive or protective purposes is permissible under the Biological Weapons Convention, but it can still send the wrong signals. It could cause countries to doubt one anothers intentions and lead to tit-for-tat investment in potentially risky research, including in self-spreading vaccines. The result of research gone awry or biowarfare could be catastrophic for health and the environment.

At a time when the norm against chemical weapons is degrading, underscored most recently by the poisoning of Russian opposition leader Alexei Navalny with the nerve agent Novichoka crime for which many European officials blame Russiathe international community simply cant afford to have the same thing happen to the norm against the use of biological weapons. It would completely defy the spirit of the treaty if it seemed like states would even want to pursue high-risk dual use activities in biology.

Early, open, good-faith conversations about scientific aims and advances that cause particular dual-use concerns, as self-spreading vaccines do, are essential to exploring the broader stakes of certain technical trajectories. The University of California, Davis program is pursuing ways to incorporate an off switch to safely control the technology. And DARPA says any field experimentation related to the project would follow biosafety protocols. But these pledges wont suffice. Our ambition must be to make a collective decision about the technical pathways we are willing, or not willing, to take as a society.

The rest is here:
Scientists are working on vaccines that spread like a disease. What could possibly go wrong? - Bulletin of the Atomic Scientists

Medical Simulator Market 2020 Will Emerge Globally And Grow upto 13.8% of CAGR by 2023 – The Daily Chronicle

The Global Medical Simulator Market size is projected to reach USD XX Mn by 2023 from USD XX Mn in 2018, at a CAGR of 13.8% during the forecast period.

Global Medical Simulator Industry Research Report Provides Detailed Insight Covering all Important Parameters Including Development Trends, Challenges, Opportunities, Key Insights and Competitive Analysis of Medical Simulator Market.

View complete Report, https://www.alltheresearch.com/report/84/Medical-Simulator

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Medical Simulator market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Medical Simulator market in terms of both revenue and volume.

Get Exclusive Sample Report on Medical Simulator Market is available at https://www.alltheresearch.com/sample-request/84

Impact of COVID-19: Medical Simulator Market report analyses the impact of Coronavirus (COVID-19) on the Medical Simulator industry. Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Medical Simulator market in 2020

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Download the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://www.alltheresearch.com/impactC19-request/84

Top 10 leading companies in the global Medical Simulator market are analyzed in the report along with their business overview, operations, financial analysis, SWOT profile and Medical Simulator products and services

Market Segmentation:

Top Players Listed in the Medical Simulator Market Report areVirtaMed, MS Tech, VRmagic, Simbionix, Gaumard Scientific, Ambu, Bioseb, CAE Healthcare, Creaplast, Medical Simulation Corporation (MSC), PerSys Medical, .

Based on type, The report split into 2D Simulator, 3D Simulator, .

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Hospitals, Diagnostic Laboratories, Research & Academic Laboratories, .

Get Special Discount Up To 50%, https://www.alltheresearch.com/speak-to-analyst/84

The study objectives of this report are:

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Contact Name: Rohit B.Email:[emailprotected]Phone: 1-888-691-6870

See original here:
Medical Simulator Market 2020 Will Emerge Globally And Grow upto 13.8% of CAGR by 2023 - The Daily Chronicle

Global Pharmacogenomics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To 2028 – The Scarlet

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Pharmacogenomics Market market.

Trusted Business Insights presents an updated and Latest Study on Pharmacogenomics Market Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Pharmacogenomics Market market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Pharmacogenomics Market 2020 (Includes Business Impact of COVID-19)

Global Pharmacogenomics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global pharmacogenomics market report has been segmented on the basis of technology, application, end user, and region.

Request Covid 19 Impact

Global Pharmacogenomics Market: Overview

Pharmacogenomics is a branch of genetics which is concerned with determining the response of an individual to particular drugs. It is a combination of pharmacology -the science of drugs and genomics which means the study of genes and their functions. Pharmacogenomics techniques are used for the development of effective and safe medications with specific genetic makeup.

Global Pharmacogenomics Market: Dynamics

Rising incidences of chronic diseases such as tuberculosis, cancer, HIV, and many others is a major factor anticipated to drive the growth of the global pharmacogenomics market over the forecast years. In addition, increasing number of geriatric population, higher adoption rate of pharmacogenomics procedure by the various healthcare professionals, and growing demand for personalized therapy are some of the other factors expected to drive revenue growth of the target market. Furthermore, higher health care expenditure and increasing incidences of lifestyle diseases are some among another factors expected to boost the demand for pharmacogenomics. However, high cost associated with test and lack of technical expertise and trained professional in developing and under developing countries are some of the major factors that may hamper the growth of target market to a significant extent.

Global Pharmacogenomics Market: Segment Analysis

Among the technology segments, polymerase chain reaction segment is expected to register the highest market share in terms of revenue as compared to other technologies. This is due to, increasing usage of PCR for in molecular biology for making many copies of a specific DNA segment and is very quick and accurate technique, resulting in higher adoption rate. Among the application segments, oncology is expected to anticipate highest market revenue share over the forecast period, owing to growing demand for the use of pharmacogenomics advent technologies in drug discovery and development for oncology treatment. Among the end user, hospitals and clinics are expected to account for significant share as compared to other end user segment. This can be due to, the presence of highly skilled and expects medical professionals with better infrastructure and advance technologies.

Global Pharmacogenomics Market: Trend

Major players are investing high amount for researcher activity in order to study the safety and efficiency of drugs. In addition, prominent manufacturers are collaborating with other research institute for carrying out clinical pharmacogenomics testing. Also, the government are funding companies that work for development of bioinformatics technology for precision medicine research applications. The above mentioned are among some of the key trends observed in the global pharmacogenomics market.

Global Pharmacogenomics Market: Regional Analysis

In 2019, the markets in North America is projected to a significant market share over the forecast period. This is primarily due to, presence of developed medical facilities and healthcare sector, increasing incidences of chronic diseases, and high patient awareness level in countries in the region. The market in the Asia Pacific is projected to register fastest growth rate over the forthcoming years. This can be primarily attributed to, increasing preference among patients for personalized treatment, increasing number of clinical trials as well as research and development activates in countries of Asia Pacific region.

Global Pharmacogenomics Market Segmentation:

Segmentation by technology:

Polymerase Chain ReactionMicroarraySequencingMass SpectrometryElectrophoresisOthers

Segmentation by application:

OncologyInfectious diseasesCardiovascular diseasesNeurological diseasesPsychiatryPain managementOthers

Segmentation by end user:

Hospitals and clinicsResearch institutionsAcademic institutes

Looking for more? Check out our repository for all available reports on Pharmacogenomics Market in related sectors.

Quick Read Table of Contents of this Report @ Global Pharmacogenomics Market 2020 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

The rest is here:
Global Pharmacogenomics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To 2028 - The Scarlet

Gene Expression Analysis Market to Surge at a Robust Pace in Terms of Revenue over COVID-19 Crisis 2018 2026 – Kentucky Journal 24

Global gene expression analysis market was valued US$ 4.2 Bn in 2017 and is expected to reach US$ 8.6 Bn by 2026, at a CAGR of 9.37 % during a forecast period.

Gene expression is a procedure of deriving information from a gene to synthesize a functional gene product. Rising use of gene expression analysis in precision medicine provides key opportunities for the market during the forecast period.

Get Access to sample pages:https://www.trendsmarketresearch.com/report/sample/6087

Falling cost of sequencing, technological advancements, increasing the prevalence of cancer, and availability of government funding are propelling the market growth. Novel technologies to aid gene expression studies, rising application areas of gene expression, and availability of gene expression databases are boosting the growth the global gene expression analysis market. Currency Devaluation is a major challenge of the market. The high cost of instruments and lack of trained professionals are hindering the market growth.

The growing volume of genetic tests in drug & biomarker discovery and pharmacogenomics applications are driving the growth of the consumables market. The rising installation of NGS & PCR tools worldwide will significantly boost the demand for consumables. PCR analysis is estimated to the largest revenue share owing to high adoption & introduction of systems integrated with other steps as well as techniques.

Pharmaceutical & biotechnology companies utilize gene expression analysis products & services to achieve their clinical research goals like drug discovery & development and biotech research. The high volume of research studies involving gene expression analysis and huge capital for high-end analysis instruments & consumables is expected to grow at the highest rate during the forecast period in the pharmaceutical and biotechnology segment.

The Asia Pacific market is expected to grow at the highest rate during the forecast period owing to the domestic manufacturing of sequencing systems, western partnerships to improve healthcare, high R&D intensity, government focus on cancer and other life science research, and flourishing bioresearch centers.

Key player operating in global gene expression analysis market are Agilent Technologies, BGI, Bio-Rad Laboratories, Inc., Eurofins Scientific, F. Hoffmann-La Roche, GE Healthcare, Illumina, Inc., Oxford Gene Technology, Pacific Biosciences of California, Inc., Perkinelmer, Inc., Qiagen N.V., and Thermo Fisher Scientific, Inc.

The Scope of Global Gene Expression Analysis Market:

Global Gene Expression Analysis Market, by Products & Services:

Consumables

Instruments

Services

Global Gene Expression Analysis Market, by End User:

Pharmaceutical & Biotech companies

Academic Institutes & Research Centers

Other End User

Global Gene Expression Analysis Market, by Region:

North America

Europe

Asia Pacific

South America

Middle East & Africa

Key Player Operating in Global Gene Expression Analysis Market:

Agena Bioscience

Applied Microarrays

Arrayit

AutoGenomics

BD

Beijing Genomics Institute

BioChain Institute

Biometrix Technology

Cepheid

CombiMatrix

Danaher

Danyel Biotech

EMD Millipore

Eppendorf

Exiqon

Fluidigm

GE Healthcare

Great Basin

LC Sciences

Luminex

Microarrays

Miltenyi Biotec

OriGene Technologies

Oxford Gene Technology

Oxford Nanopore Technologies

Partek

Perkin Elmer

Phalanx Biotech Group

Promega

Takara Bio

Tecan

Veredus Laboratories

Zyagen.

More Info of Impact COVID-19@https://www.trendsmarketresearch.com/report/covid-19-analysis/6087

Read the original post:
Gene Expression Analysis Market to Surge at a Robust Pace in Terms of Revenue over COVID-19 Crisis 2018 2026 - Kentucky Journal 24

Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for…

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Genomind, the leader in comprehensive genetics and digital mental health services, has pioneered a new level of specificity and accuracy for cheek swab-based pharmacogenetics tests.

Genominds Professional PGx Express test provides clinicians with a comprehensive report of up to 24 genes that delivers important prescribing guidance designed to help reduce the traditional process of trial and error with mental health medications. Genomind has served over 15,000 clinicians and tested over 270,000 patients for this important treatment guidance. The FDA includes pharmacogenetic biomarker warnings, precautions and drug-drug interaction guidance on the labels of over 270 medications (https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling).

Two of the most important genetic variants which Genominds Professional PGx Express tests for are HLA-B *15:02 and HLA-A*31:01. These genes are part of the complex human leukocyte antigen (HLA) system that is among the most highly variable DNA regions in humans and is central to autoimmune diseases and transplant rejection. Both of these variants are associated with an increased risk of serious, sometimes fatal, skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, in the presence of carbamazepine (as well as oxcarbazepine and phenytoin for HLA-B*15:02).

Carbamazepine is indicated for the treatment of epilepsy and trigeminal neuralgia, and is commonly used for individuals with mood disorders, such as bipolar disorder. It is on the World Health Organizations List of Essential Medicines1 and was prescribed over 3.5 million times in 2019, a number that experts say will increase in 20202.

In contrast to HLA-B*15:02, the HLA-A* 31:01 allele is more common in Caucasians, while also occurring in individuals of Hispanic/South American and East Asian descent. Carbamazepines FDA label contains warnings about this gene-drug pair, as does the Clinical Pharmacogenetic Implementation Consortium (CPIC).

Until recently, commercial PGx assays commonly tested for this allele using a surrogate tag SNP (single nucleotide polymorphism) method. During a recent validation exercise, Genomind identified a very high false positive rate of approximately 40%, with this common industry method. This means with the traditional testing method, 40% of the positive tests would incorrectly identify someone as being at risk of serious adverse events with carbamazepine treatment, thereby inappropriately excluding a potentially useful agent.

Genominds CEO Shawn OBrien was inspired to find a better solution. Our company is all about our I-CAIRE culture (integrity, collaboration, accountability, innovation, respect and excellence), so when we discovered this shortcoming in the industry, we immediately set about finding a better solution to help more clinicians and patients.

Genomind scientists, led by CSO Dr. David Robbins, developed an innovative and proprietary real-time PCR (polymerase chain reaction) test that is highly specific for HLA-A*31:01. The increased specificity of this assay also makes the need for confirmatory testing unnecessary for individuals testing positive. In validation testing of this new and improved assay, specificity and sensitivity were 100%. In real-world testing we expect specificity to be >99%. This means we will be able to reduce the 40% of false positives down to a fraction of a percentage3. This PCR-based testing was validated by comparing random anonymized patient samples with HLA typing by Next Generation Sequencing (NGS) through a third party lab. FDA considers NGS as the gold standard for HLA typing. The validation was further supported by testing samples from the Coriell Institute for Medical Research with documented rare and common HLA-A types. Genomind filed a patent on this important breakthrough and is the only comprehensive mental health genetics test with this capability on the market.

This novel innovation uniquely provides much greater accuracy in identifying patients at risk for a serious drug reaction and provides greater and safer access of a potentially helpful medication, carbamazepine, for individuals previously thought to be at risk said Dr. Scott Aaronson, MD, Clinical Assistant Professor of Psychiatry at the University of Maryland School of Medicine and Distinguished Fellow of the American Psychiatric Association.

With Medicares recently published new Local Coverage Determination allowing coverage of tests like Genominds, and with United Healthcares positive coverage policy, the Mental Health PGx industry is expected to see major growth. Therefore, it is critical that clinicians have access to the most accurate and specific PGx results.

To this end Genomind is offering a major national digital education effort for clinicians and patients. They are starting with their 15,000 clinicians and providing education materials, access to their acclaimed On-Demand Hotline or scheduled consults, and free access to their state-of-the-art precision medication management software, G-DIG (Genomind Drug Interaction Guide.) Genomind will also be reaching tens of thousands of the highest prescribers of mental health medications and millions of potential patients with their digital communications engine that generates millions of hits and video views on their website annually. Genomind is offering all their advanced services and software to any new registering clinician.

About Genomind

Genomind is a leading precision mental health company singularly focused on filling the innovation gap in mental health care through novel, genetics-based tools. Supported by a world-class genetics lab, a unique heritage of clinical mental health expertise, clinical collaboration and consultation, state-of-the-art digital tools and telemental health enabling services, Genomind is empowering a new standard of care. Its flagship product, Genomind Professional PGx Express, is the most comprehensive pharmacogenetic testing service helping medical professionals personalize patients mental health treatment. The Company also recently launched Genomind Mental Health Map a breakthrough direct-to-consumer test that enables a new and better understanding of the biological basis of mental wellness, coupled with personalized actionable guidance to help people improve health and wellness. Learn more at http://www.genomind.com.

(1) World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

(2) "Carbamazepine - Drug Usage Statistics". ClinCalc. Retrieved 11 April 2020.

(3) This fraction of a percent represents the real world use HLA-A*31 types other than 31:01 (ie. HLA-A*31:04, 31:12, and 31:16) which may rarely cause false positive results. That being said, it is not known if these types are associated with skin disorders following use of carbamazepine.

Read more from the original source:
Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for...

Global Genomic Medicine Market to Witness Stellar Growth Rate in the Next 10 Years – Jewish Life News

The National Human Genome Research Institute definesgenomic medicine asan emerging medical discipline that involves using genomic information about an individual as part of their clinical care (e.g., fordiagnostic or therapeutic decision-making) and the health outcomes and policy implications of that clinical use. Genomic medicine is a type of precision medicine in which genomics, epigenomics and other related data is used to accurately aid in individual disease diagnosis. Genomic medicine has novel applications in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious disease.Genomic medicine paves way for personalized medicine into clinics and has immense potential to reach the physicians and patients. Genomic medicine has been used for advanced sequencing in cancer pharmacogenomics, rare disorder diagnosis and for tracking of outbreaks of infectious diseases.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/11323

Genomic Medicine Market: Drivers & Restraints

Backed by government investments in precision medicine initiatives such as a multimillion dollar investment by President Obama in January 2015 which aims to improve how to treat and prevent a disease by laying emphasis on its genetic makeup is expected to boost the market growth. Clinical validity and utility of genomic medicine tests is a major issue witnessed in the global market. Also, lack of awareness among healthcare professionals, sluggish adoption of genome medicine, fluctuating regulatory landscape are the factors which could hamper growth of the global genomic medicine market.

Genomic Medicine Market: Segmentation

The global genomic medicine market is classified on the basis of application type, end use and region.

Based on application, the global genomic medicine market is segmented into the following:

Based on end use, the global genomic medicine market is segmented into the following:

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/11323

Genomic Medicine Market: Overview

Genomic medicine is gaining momentum with expanding applications ranging from risk assessment and diagnosis in healthy individuals to genome-based treatment for patients with complicated disorders. Oncology is a major application of genomics medicine during cancer screening process as diagnostics for genetic and genomic markers. Oncology segment is expected to account for a major share in the global genomic medicine market. Genomic medicine is increasingly being used not only for research purpose but also in clinical applications. In clinical applications, genomic medicine will potentially enhance patient care.

Genomic Medicine Market: Region wise Overview

Geographically, global Genomic Medicine market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan (APEJ), Japan, Middle East and Africa (MEA). Owing to the presence of large number of academic as well as research institutions in the U.S. which are working on genomic medicine to discover next-generation genomic medicines, North America region is projected to lead the global genomic market in terms of value during the forecast period. Also, the presence of several universities offering educational programs coupled with opportunities in scientific research of genomic medicine in the North America and Europe is expected to have positive impact on the regional markets. The genomic medicine concept still in its nascent stage is yet to receive an impetus from the emerging market which are anticipated to hold smaller shares in the global market.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/11323

Genomic Medicine Market: Key Players

The key research institutes in global genomic medicine market are

The focus of the top players will be on the identification of effective drug candidates particularly in cancer treatment based on the molecular structure of tumors.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, accessories and applications.

Here is the original post:
Global Genomic Medicine Market to Witness Stellar Growth Rate in the Next 10 Years - Jewish Life News

The Formative Four: Top Health IT Capabilities That Will Improve Medication Management – Pharmacy Technology Report

Katherine CappsMolly Ekstrand, BPharm, BCACP, AE-C

Pharmacists well understand that medication is part of the daily lives of many Americans. In fact, studies show nearly 75% of visits to physician offices and hospital outpatient clinics involve medication therapy, and almost 30% of adults take five or more medications. Unfortunately, suboptimal medication use leads to at least 275,000 deaths annually and costs more than $528 billion.

Recently, our organization, The Get the Medications Right (GTMRx) Institute, in Tysons Corner, Va., released a report outlining steps for medication management reform, including a call for comprehensive medication management, or CMM. This comprehensive management is an evidence-based process of care that personalizes the approach, resulting in better care, reduced costs, and improved patient satisfaction and provider work life.

The report, the GTMRx Blueprint for Change, includes recommendations outlining how each stakeholder can get involved to improve patient carefrom physicians to clinical pharmacists, health plan sponsors, providers, consumer groups, employers as health plan sponsors, and policymakers.Many things need to change, but technology and information technology (IT) capabilities are central in the challenge for reform.

Here, we outline four health IT categories to achieve medication optimization through CMM, enabling a broad practice adoption of a systematic approach to medication use throughout the continuum of care. Software supports the practice management systems developed around CMM workflows and thought processes, driving consistency of the CMM service. Within each of these categories, organizations will undergo a journey toward maturity. However, considerations in each of these categories are foundational.

1. Clinical Decision Support Tools (at the point of care): Access to diagnostic results, clinical notes, patient status and other clinical information allows care teams to fulfill important activities in the CMM process. This information offers insight into patients experiencing medication therapy problems, and it helps the clinicians determine whether or not the patient has achieved the clinical goals of therapy. Having the ability to evaluate actual use patterns of all medications (e.g., over the counter, supplements, prescribed drugs and biologics) also is important. This full view of information is essential for the medication expert to properly assess each medication for appropriateness, focusing on the achievement of the clinical goals for each therapy. Organization and interpretation of these data in a medication-centric workflow can improve the efficiency and efficacy of clinical decision making. A medication-related dashboard should have the ability to support anyone on the care team, allowing them to make simple, streamlined decisions about a patients medication therapy. This dashboard should include objective data that help clinicians decide whether a patient needs a higher level statin, the blood pressure medicine should be increased, or pharmacogenomic data are needed to assess the safety or efficacy of the medications.

2. Population Health and Risk Stratification Tools: Health care resources are finite. There are certain patient populations that benefit more from CMM services. Tools that integrate data from electronic health records (EHRs), pharmacies, health plans and other reliable sources can provide the foundation for deployment of comprehensive risk models. Risk modeling tools allow payor, provider or value-based networks to easily identify the patients who are at risk and will benefit most from CMM services. Health systems, pharmacies, payors and prescribers should also have the ability to proactively reach out and invite at-risk patients to participate in CMM services, effectively automating a process and decreasing administrative burden from the point-of-care clinician.

3. Patient Engagement and Care Coordination Tools: Health IT should enable and facilitate the exchange of information between the patient and care team. Patients gather information in various forms that can inform clinical decisions regarding medication therapy. The tools should have the ability to integrate the digital therapeutic health information from a patient with the pharmacogenomic data that clinicians currently receive as a separate, cumbersome report. These types of information would come together in an EHR in a usable fashion. Health IT can facilitate bidirectional communication between the pharmacist, clinician and patient. Clinicians should have the ability to effectively and efficiently communicate across the continuum of care. In many cases, the patients care team, including the pharmacist providing comprehensive medication management, are not colocated and do not share a single EHR platform. Its imperative that health IT has the ability to enable bidirectional, secure health-related data exchange to promote optimal medication use.

4. Health IT Supporting Economic, Clinical and Humanistic Outcomes: Purpose-built software can drive consistency and demonstrate the value of CMM practice. Software ensures the capture of compliance and regulatory reporting requirements unique to CMM services. The tools should have the ability to allow the team to identify medication therapy problems in a systematic way, with the ability to gather and analyze information across systems and care settings. The tools should have the ability to track participation, offer point-of-care insight to the clinician, and, in order to efficiently identify medication therapy problems, record the defined medication care plan and steps toward resolution.

CMM services can be correlated with broader changes in health status or health care utilization patterns, thus demonstrating contribution and value to the broader health care system. However, optimizing medication use through CMM in practice truly and wholly relies on having the right data, at the right time, at the point of care and available to the entire team.

Ms. Capps is the co-founder and executive director of the GTMRx Instituteusvuwtdtxr, a catalyst for change that brings critical stakeholders together, bound by the urgent need to get the medications right. Ms. Ekstrand is a distinguished fellow at GTMRx.

See original here:
The Formative Four: Top Health IT Capabilities That Will Improve Medication Management - Pharmacy Technology Report

Genetic Testing Services Market: Surge in Adoption of Genetic Testing Services to Boost the Market – BioSpace

Transparency Market Research (TMR) has published a new report titled, Genetic Testing Services Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20192027.According to the report, the global Genetic Testing Services market was valued at US$ 41.2 Bn in 2018 and is projected to expand at a CAGR of 7.3% from 2019 to 2027.

Overview

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=10235

New Born Screening Segment to Dominate Global Genetic Testing Services Market

Request for Analysis of COVID19 Impact on Genetic Testing Services Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=10235

Oncology Segment Hold a Major Share of Global Genetic Testing Services Market

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=10235

Hospitals based laboratories Segment to Dominate Global Genetic Testing Services Market

North America to Dominate Global Genetic Testing Services Market

Buy Genetic Testing Services Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=10235&ltype=S

Competitive Landscape

The global genetic testing services market is consolidated in terms of number of players. Key players in the global Genetic Testing Services market include Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Genomic Health, Inc., NeoGenomics Laboratories, Inc, Eurofins Scientific, Ambry Genetics, Illumina, Inc, 23andMe, Inc., Exact Sciences, Natera, Invitae, Veracyte, and other prominent players.

Browse More Trending Reports by Transparency Market Research:

Nitinol Stents Market: https://www.transparencymarketresearch.com/nitinol-stents-market.html

Neurology Sterile Injectable Market: https://www.transparencymarketresearch.com/neurology-sterile-injectable-market.html

Microplate Systems Market: https://www.transparencymarketresearch.com/microplate-systems-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

Read the rest here:
Genetic Testing Services Market: Surge in Adoption of Genetic Testing Services to Boost the Market - BioSpace

It’s Time to Cast a Wider Net With DPD Testing – Medscape

This transcript has been edited for clarity.

I'm David Kerr, professor of cancer medicine at the University of Oxford. One of my abiding interests has been to apply my old training in clinical pharmacology to how I deliver cancer medicine. I've been a cancer doc for 30 years and one of the recent roads I've traveled has been trying to incorporate pharmacogenetics into my clinical decision pathway. I'm a gastrointestinal oncologist; I treat patients predominantly with colorectal, gastric, and pancreatic cancers. Therefore, the fluoropyrimidines 5-fluorouracil (5-FU) and capecitabine are a central part of my therapeutic armamentarium.

I've talked before about the relevance of the pharmacogenomics of fluoropyrimidines and dihydropyrimidine dehydrogenase (DPD). This is a rate-limiting catabolic enzyme which is responsible for breaking down and destroying fluoropyrimidines. Therefore, it's terribly important. If we find genetic variance which reduces the activity of the enzyme, you get a concomitant increase in the plasma concentration of the 5-FU, and consequently much worse toxicity even to the point of death in some situations or extremely bad toxicity. This is compounded by the fact that 5-FU has nonlinear pharmacokinetics; that means for a small increase in dose you can get a very large increase in plasma concentration. It's a very complicated kinetic situation to be in.

We've instituted DPD testing in our institute in Oxford, I think successfully, and we're seeing a very significant change in reduction in the number of patients being admitted to wards with severe toxicity. I think DPD tests are very good at predicting life-threatening myelosuppression and risk of death, but they're not so good at fluoropyrimidine-induced diarrhea and mucositis.

One thing that interests me, and this is perhaps a more philosophical than scientific question, is how widely do we cast the ethnic net when we build a pharmacogenetic test? I do a lot of work in China. The single nucleotide polymorphisms (SNPs) we've discovered, based on our Western databases, don't apply as readily to our patients who are citizens of Eastern Asian countries.

I have many friends in the Middle East, having worked in Qatar, and I have very strong associations with colleagues in Saudi Arabia and the Middle East. We know that the Arab genome looks significantly different. Also, I work in sub-Saharan Africa, and the SNPs we see in DPD again have different frequencies and prevalences in the African population.

All of us live within a multiethnic society. Although patients in my hospital are predominantly Caucasian, it still seems to me important that we incorporate SNPs, which allow us to detect the possibility of these variants if we're seeing patients from Africa or from other ethnic groups. Rather than focusing and narrowing down in a very small SNP set, as is sometimes recommended, I would rather we had an expanded SNP set, especially in the time of next-generation sequencing when it's relatively easy to expand the SNP signature algorithm to include these different ethnic groups.

We have had a couple of Eastern African patients where, if we had not done the wider SNP that we helped to develop, we would have missed the possibility of being able to dose-reduce somebody who would undoubtedly have had life-threatening toxicity if we'd gone ahead with conventional treatment.

Why is that a philosophical question? So far, pharmacogenomics has been predominantly driven from the West in Caucasian populations. With precision medicine, of course, we understand that we can shape, change, or alter the SNP panel to suit one's local population an Arab SNP test, a Chinese SNP test, and so on. But if we live in a multiethnic society in which we serve a population of patients of many different ethnicities, shouldn't we have a pan test to cover the spectrum of these so that if we do have patients coming from different ethnic backgrounds, a single test with the appropriately wide SNP signature would serve all rather than some? Something to think about.

I would be very interested in your comments and I'd be very happy to engage in discussion about this. For the time being, Medscapers, over and out.

David J. Kerr, CBE, MD, DSc, is a professor of cancer medicine at the University of Oxford. He is recognized internationally for his work in the research and treatment of colorectal cancer and has founded three university spin-out companies: COBRA Therapeutics, Celleron Therapeutics, and Oxford Cancer Biomarkers. In 2002, he was appointed Commander of the British Empire by Queen Elizabeth II.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

See the original post:
It's Time to Cast a Wider Net With DPD Testing - Medscape

Pharmacogenomics Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis Report by 2027 …

The major driving factors for the growth of this market in the North American region is the rising demand for personalized medicines, high medical reimbursement facilities, and technological advancement.

The Pharmacogenomics market analysis report ismainly focused on leading market players. Our analysts have provided information on financial statements of these players, product benchmarking, and their key business development strategies.

Claim Your FREE Sample Copy with Table of [emailprotected] https://www.emergenresearch.com/request-sample-form/88

Key participants include Abbott Laboratories, Admera Health, LLC, Agena Biosciences, Inc., Cancer Genetics, Inc., Dynamic DNA Laboratories, F. Hoffmann-La Roche Ltd, geneOmbio Technologies Pvt Ltd., Genomic Health, Inc., Illumina, Inc., and Laboratory Corporation of America Holdings, among others.

Pharmacogenomics Market Overview:

The latest market study broadly segments the industry based on the product type range, application gamut, end-use industry, key regions, and the competitive background. One of the central components of the report is a detailed explanation of the gross profits, revenue shares, sales volume, manufacturing costs, individual growth rate, and the financial standing of the leading market players. The developmental scope of the Pharmacogenomics markets new entrants and established companies has also been emphasized in the report.

Check Our [emailprotected]https://www.emergenresearch.com/select-license/88

Product and Services Outlook (Revenue, USD Billion; 2017-2027)

Products

Kits

Assays and Reagents

Instruments

Software

Services

Genotyping

SNP Identification

Pharmacogenetic Testing

Other Services

Technology Outlook (Revenue, USD Billion; 2017-2027)

Polymerase Chain Reaction (PCR)

Real-Time PCR

qPCR

Digital PCR

DNA Sequencing/Next Generation Sequencing (NGS)

Nucleic Acid Amplification Tests (NAATs)

Mass Spectrometry

Gel Electrophoresis

Hybridization

Fluorescence In Situ Hybridization (FISH)

Chromogenic In Situ Hybridization (CISH)

Others

Microarray

Others

Application Outlook (Revenue, USD Billion; 2017-2027)

Oncology

Infectious Diseases

Neurology/Psychiatry

Cardiovascular

Others

End-Use Outlook (Revenue, USD Billion; 2017-2027)

Research Organization

Pharmaceutical Companies

Diagnostic Centers

Others

In market segmentation by geographical regions, the report has analysed the following regions-

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Click to access the Report Study, Read key highlights of the Report and Look at Projected [emailprotected] https://www.emergenresearch.com/industry-report/pharmacogenomics-market

Table of ContentChapter 1. Methodology & Sources1.1. Pharmacogenomics Market Definition1.2. Research Scope1.3. Methodology1.4. Research Sources1.4.1. Primary1.4.2. Secondary1.4.3. Paid Sources1.5. Pharmacogenomics Market Estimation TechniqueChapter 2. Executive Summary2.1. Pharmacogenomics Market Summary Snapshot, 2021-2028Chapter 3. Pharmacogenomics Market Key InsightsChapter 4.Pharmacogenomics Market Segmentation & Impact Analysis4.1.Pharmacogenomics Market Segmentation Analysis4.2. Pharmacogenomics Industrial Outlook4.2.1. Market indicators analysis4.2.2. Pharmacogenomics Market drivers analysis4.2.3. Pharmacogenomics Market restraints analysis4.3. Technological Insights4.4. Regulatory Framework4.5. Porters Five Forces Analysis4.6. Competitive Metric Space Analysis4.7. Price trend Analysis4.8. Covid-19 Impact Analysis

Click to access the Complete Pharmacogenomics Market ReportTable of Content: https://www.emergenresearch.com/industry-report/pharmacogenomics-market

Thank you for reading our report. Customization of the report is available as per client requirements. Kindly get in touch with us to know more about the report.

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Explore our related report from different Publications:

Smart Irrigation Controllers MarketTo Be Worth USD 732.7 Million by 2027 Growing at a CAGR of 14.9% | Emergen Research

Soldier System Marketto Reach USD 15.19 Billion By 2027 Growing at a CAGR of 4.8% | Emergen Research

Plant-Based Food & Beverage Alternatives Marketto Reach USD 32.29 Billion By 2027 | Emergen Research

Nano Drones Marketto Reach USD 4.04 Billion By 2027 Growing at a CAGR of 26.8% | Emergen Research

Fermented Food and Ingredients MarketTo Be Worth USD 875.21 Billion by 2027 | Emergen Research

Signal Intelligence (SIGINT) Marketto Reach USD 18.28 Billion By 2027 | Emergen Research

Sodium Dichromate MarketTo Be Worth USD 1,242.4 Million by 2027| Emergen Research

Industrial Microbiology MarketTo Be Worth USD 17.71 Billion by 2027| Emergen Research

Surgical Instrument Tracking Systems MarketTo Reach USD 431.6 Million by 2027| Emergen Research

Medical Lighting Technologies MarketSize To Be Worth USD 2.99 Billion by 2027 | Emergen Research

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web:www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail:[emailprotected]

Facebook|LinkedIn|Twitter|Blogs

Continued here:
Pharmacogenomics Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis Report by 2027 ...

Pharmacogenomic (PGx) Testing Market to Witness Comprehensive Growth by 2018 to 2028 – The Daily Chronicle

Analysis of the Global Pharmacogenomic (PGx) Testing Market

A recent market research report on the Pharmacogenomic (PGx) Testing market published by Fact.MR is an in-depth assessment of the current landscape of the market. Further, the report sheds light on the different segments of the Pharmacogenomic (PGx) Testing market and provides a thorough understanding of the growth potential of each market segment over the forecast period (20XX-20XX).

According to the analysts at Fact.MR, the Pharmacogenomic (PGx) Testing market is evenly poised to register a CAGR growth of ~XX% during the assessment and surpass a value of ~US$ XX by the end of 2029. The report analyzes the micro and macro-economic factors that are likely to impact the growth of the Pharmacogenomic (PGx) Testing market in the upcoming years.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=3143

Key Insights Enclosed in the Report

Segmentation of the Pharmacogenomic (PGx) Testing Market

The presented report dissects the Pharmacogenomic (PGx) Testing market into different segments and ponders over the current and future prospects of each segment. The report depicts the year-on-year growth of each segment and touches upon the different factors that are likely to influence the growth of each market segment.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=3143

COVID-19 Analysis

The report encompasses the major developments within the global Pharmacogenomic (PGx) Testing market amidst the novel COVID-19 pandemic. The report offers a thorough understanding of the different aspects of the market that are likely to be feel the impact of the pandemic.

Important doubts related to the Pharmacogenomic (PGx) Testing market clarified in the report:

Why Choose Fact.MR

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=3143

Follow this link:
Pharmacogenomic (PGx) Testing Market to Witness Comprehensive Growth by 2018 to 2028 - The Daily Chronicle

Global Pharmacogenomics Market Overview With Detailed Analysis, Competitive Landscape, Emerging Trends , Future Prospects during 2020-2027 – Scientect

The research report on Pharmacogenomics Market gives todays industry data and upcoming developments, allowing you to know the products and quit customers using sales rise and profitability of the market. The record gives a detailed analysis of key drivers, leading market key players, key segments, and regions. These understandings provided in the record would advantage market players to formulate strategies for the destiny and benefit a robust role within the worldwide market.

Click here to get a sample of the premium report:

https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#request_sample

Major Companies Covered in Research Report:

Bayer AGBecton, Dickinson and CompanyAffymetrix, Inc.F. Hoffmann-La Roche AGQIAGENAbbott Laboratories, Inc.Bio-Rad Laboratories, Inc.Thermo Fisher Scientific Inc.Illumina, Inc.AstraZeneca PLC

Regional segmentation of the Pharmacogenomics market:

The report also provides the latest market dynamics, industry news like mergers, acquisitions, and investments. The report can help to realize the market and strategize for business expansion accordingly. In the scheme analysis, it gives insights from marketing channel and market positioning to probable growth strategies, providing comprehensive analysis for new entrants or exists competitors in the Pharmacogenomics industry.

Get Upto 40% [emailprotected]

https://www.reportspedia.com/discount_inquiry/discount/58762

This detailed market study is centered on data obtained from multiple sources and is analyzed using various tools. These tools are engaged to achieve insights on the potential assessment of the industry, facilitating the market strategists with the latest development opportunities. Moreover, these tools also deliver a comprehensive analysis of each application/product segment in the global Pharmacogenomics Market.

Pharmacogenomics Market Segment considering Production, Revenue (Value), Price Trend by Type:

DNA SequencingMicroarray, Polymerase Chain ReactionElectrophoresisMass SpectrometryOthers

Pharmacogenomics Market Segment by Consumption Growth Rate and Market Share by Application:

Drug DiscoveryTailored TreatmentOncologyPain ManagementOther Therapeutic Applications

Inquire or Share Your Questions If Any before the Purchasing This Report

https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#inquiry_before_buying

The key questions answered in Pharmacogenomics report:

Table of Content:

For Detailed TOC @

https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#table_of_contents

See the rest here:
Global Pharmacogenomics Market Overview With Detailed Analysis, Competitive Landscape, Emerging Trends , Future Prospects during 2020-2027 - Scientect

How intelligent data transforms health in the time of COVID-19 – Mobihealth News

About the author:Dr. Liz Kwo is currently the staff VP of clinical data analytics at Anthem, and previously cofounded and served as CEO of telemedicine second opinion company InfiniteMD. She received anMDfrom Harvard Medical, an MBA from Harvard Business School and an MPH from the Harvard T.H. Chan School of Public Health.

COVID-19 has reshaped the way humans interact with technology in healthcare. Many countries have responded with public health measures such as social distancing, masks, and quarantine for suspected and confirmed cases.Intelligent data, technology, artificial intelligence (AI)and machine learning (ML) havestarted to lighten the burden to establish new ways for both health system supply and demand sustainability.

Among the most visible promoters of digital health arenext-generation payers and providers (NGPPs). These companies, many of them created after implementation of the Affordable Care Act (ACA), have commonly adopted the belief that technology is the solution to improving the healthcare system. Their focus is on delivering technology-enabled solutions to improve clients, such as employers' but more importantly, patients' as the end-user's experiences. These companies are using concepts such as blockchain, telehealth, web applications and genomics.

COVID-19 has prompted more healthcare organizations to embrace the idea of intelligent data as a tool for migration to digital health. Several companies are teaming up with startups that have the means to deliver technology-enhanced solutions either by allowing these startups to connect to their systems or by creating a customer-vendor type of relationship.

Connecting a smaller startup to a healthcare companys mainframe or command center means the startup involved in the process must codevelop solutions customized to the systems processes, flows, infrastructure and objectives. By accessing the companys platforms, whether a payor or provider through an electronic health record (EHR), a customer relationship management(CRM) system or other approach, the startup provides valid solutions based on the current status.

The solutions are not limited to identifying problems and providing fixes, but must extend to presenting innovations that enable the company to improve their patient records, deal more efficiently with aggregated and dispersed data, and handle a larger amount of information collected from various sources.

For example, collecting data run through predictive analytics via biometric devices that are connected remotely enables clinicians to complete their tasks at a higher speed with increased accuracy if the insights are actionable, potentially reducing medical costs if treatment or interventions can be determined correctly that arecustomized to the patient.

However, the downside of this type of cooperation is that it requires mobilization of massive internal resources, a relationship built on mutual trust and the willingness to share the risk among stakeholders such as providers, technology-enablement service companiesand payors. Therefore, health companies look to startup companiesfor innovative solutions that can be easily integrated in their workflows with ready-to-implement solutions, such as technology enabling remote consults between patients and care providers.

AI, for instance, requires multiple levels of mutual agreement between the healthcare companies and collaborative startups for processes such as data sharing privacy and security, liability protections, validation of models, and ongoing monitoring of progress and milestones. The implementation of AI in clinics has specific requirements, such as the availability of a workforce trained to use digital tools, remote access to the latest technologies, and knowledge and willingness from both clinicians and patients to adopt these tools.

AI has produced valuable techniques that are in place and will continue to improve in triaging care via chatbots, models for data integration that enable a better and faster illness prognosis, predicting illness progression through medical records, and detecting anomalies for fraud prevention in claims or to ensure proper claims payments.

Blockchain provides a change of secure and accurate information between nodes (e.g. patients, organizations andclinicians) with the help of a databasethat doesnt require control from a third party. Blockchain enables organizations to conduct trusted transactions and to reduce their administrative costs by sharing a common ledger instead of maintaining their own, separate data.

All the organizations participating in the blockchain have access to the shared data and can instantly protect it if accessed by unauthorized users. In the healthcare sector, blockchain is still in the early stages, and faces challenges such as the network effect, meaning that all parties sharing the blockchain must be willing to work together in testing and evaluating the advantages of this technology, which is easier said than done.

Deploying blockchain for provider access can mean that patients who are not able to find a doctor in their network can have access to a wider pool of physicians, hence benefiting from faster and improved access to care.

Telehealth (also referred to as e-health, mobile-healthor telemedicine) represents a means to remotely access medical services with the help of digital technologies such as laptops, smartphones and any mobile devices.

Among the objectives of telemedicine:

Examples of what telehealth can provide include:

Telehealth was used before COVID-19 in various formsas an instrument to train doctors in treating complex diseases in rural areas via video conference, such as the partnership between Medicaid and Extension for Community Healthcare Outcomes (ECHO) put in place at the University of Mexico,or as remote consultations with the use of symptom checkers defined by user inputs adopted in Spain by Mediktor.

COVID-19 brought a huge increase in Telehealth adoption. In the U.S., telehealth became used by 45% of consumers in COVID-19 era, compared to 11% of consumers in 2019 that called on this method to replace healthcare trips to the doctors office. Before the pandemic, the main players in the U.S. telehealth sector focused their services on urgent care areas by providing patients telehealth visits on demand. If before COVID-19 the estimated yearly revenues of U.S. telehealth companies were $3 billion, its estimated that in the next years up to $250 billion of current U.S. healthcare market could be invested in the virtualization of medical assistance through telehealth.

Telehealth, however, has its own challenges. Providers will need to adopt new ways of working;the exchange of concise and useful information must be improved;wider access and integration of technology is required;and clear data security measures must be in place. The effectiveness of telehealth compared to in-person visits will be closely measured, and reimbursement policies will have to be established and implemented properly.

For patients, the awareness and education of telehealth benefits must be understood, such as specific use cases to transmit valid information, the medical needs that telehealth can address, and understanding the insurance coverage of the service. These challenges can be surmounted, considering telehealth has the potential to bring benefits for patients, decrease costs for payers, increase efficiency for medical staffandimprove overall healthcare experience.

Web applications were developed as a response to the consumers expectations to have instant access to information. The healthcare market is currently dominated by two types of applications: ones that collect and record data regarding the health of clients (that can be shared with care providers and health insurance companies) and applications that provide access to health-related information such as health and wellness programs or provider and medical recommendations.

Mobile applications provided by some health insurance companies offer clients the opportunity to become more engaged in building their own team of healthcare providers, in order to compare prices of various services and to have autonomy in their overall health. With a few clicks, patients can locate providers inside and outside their network, choose an emergency room or urgent care center they need, or find a specialist that is available with a next-day appointment.

Many applications are populated with a huge database that delivers enormous amounts of informationin multiple languageson topics such as diseases, symptomsand medications, and are reviewed by prestigious medical professionals. Other applications are focused on prevention, helping people maintain good health by focusing them on behaviors such as motivational exercise or mindful eating, as in controlling consumption by documenting the foods they intend to eat and the impact on their health. They can calculate the caloric intake and compare foods to make better decisions.

Aside from the benefits brought to patients, web applications help providers collaborate with their patients. Applications that measure and monitor patient heart rates and blood sugar levels are equipped with triggers that send alerts when indicators reach a certain level. The alert is sent to the doctors that monitor those clients. Based on the reading and the medical history,the doctors can suggest a next step. As more people adopt these web applications, the tools will only become easier and faster to use as they improve over time.

The human genome, considered the blueprint of the human body, holds the potential biological plan for each individual. The link between a typical genome versus variants that may lead to disease can be established by analyzing a huge amount of medical records and genetic data. This is a complex, time-consumingmatching process.

The combined use of AI, machine learningand genomics brings to healthcare what has been missing in this discovery process: simplification and more accurate results in a lot shorter period of time. This can be achieved by integrating, for example, genomics with lab results, EHRs that include pathology, and imaging. T

This integration provides a more comprehensive look into a patient, which translates into better decisions taken by a supervising doctor andthe improved ability to forecast disease and to provide customized treatment and medication based on prediction patterns and the efficacy of a medication for the individual. By improving the ability to predict and treat, the costs of healthcare can be reduced by eliminating unnecessary lab tests or ineffective treatments.

The challenge in utilizing genomic data is translating this knowledge to real-world use cases. Pharmacogenomics is the use of genetic testing to inform medication-management decisions, which can improve patient outcomes and reduce health cost. For example, genomic data is used to determine treatment options for cancer patients.

This type of precision medicine creates a new consumer healthcare market for people to determine the influencing factors of their health, with extraordinary levels of treatment personalization across various chronic conditions. As patients ask their providers for advice and payers for coverage in this growing market, providers will need clear training to understand the right tests to order, how to interpret the results, and how to properly inform their patients about the results.

The costs of these tests have significantly decreased over time, but an adequate understanding of the benefits is required to achieve actionable insights from the results.

The progress made in intelligent data and AI use in the healthcare sector is surging. It is vital to ensure that all patients have access and affordable healthcare utilizing efficient tools and customized treatments that rely on intelligent data for groundbreaking innovations in healthcare.

Link:
How intelligent data transforms health in the time of COVID-19 - Mobihealth News

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: What Will COVID 19 Bring in Coming Days: F Hoffman La Roche, Agilent…

Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost and revenue during the forecast period from 2020 to 2027. A Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market that includes Future Trends, Current Growth Factors, Meticulous Opinions, Facts, Historical Data and Statistically Supported And Industry-Validated Market Data.

This Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market research provides a clear explanation of how this market will make a growth impression during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

RequestSample PDF of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report https://www.worldwidemarketreports.com/sample/121299

F Hoffman La Roche, Agilent Technologies, Thermo Fisher Scientific Inc., GE Healthcare, Pfizer, Qiagen NV, Leica Biosystems Nussloch GmBH are some of the major organizations dominating the global market.

(*Note: Other Players Can be Added per Request)

Key players in the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market were identified through a second survey, and market share was determined through a first and second survey. All measurement sharing, splitting and analysis were solved using a secondary source and a validated primary source. The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure. The combination of these two factors will help key players meet the market reach and help to understand offered characteristics and customer needs.

The report also makes some important suggestions for the new Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market project before evaluating its feasibility. Overall, this report covers Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market Sales, Price, Sales, Gross Profit, Historical Growth and Future Prospects. It provides facts related to mergers, acquisitions, partnerships and joint venture activities prevalent in the market.

This report includes market size estimates of value (million US $) and volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market, estimating the size of various other submarkets in the overall market. Major players in the market were identified through secondary studies, and market share was determined through primary and secondary studies. All ratio sharing, splitting and analysis were determined using the secondary source and the identified primary source.

What Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market report offers:

Regions Covered in This Report

Complete knowledge of the Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market is based on the latest industry news, opportunities and trends in the expected region. The Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) market research report provides clear insights into the influential factors expected to change the global market in the near future.

Remarkable Attributes of Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Report:

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

See the original post:
Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market: What Will COVID 19 Bring in Coming Days: F Hoffman La Roche, Agilent...

Gravity Diagnostics Partners with Kroger Health to Expand COVID-19 Testing with Home Collection Kits – News- Graphic

COVINGTON, Ky., July 1, 2020 /PRNewswire/ --Gravity Diagnostics, a CLIA laboratory headquartered in Covington, Kentucky, today announced the U.S. Food and Drug Administration (FDA) has granted an update to their Emergency Use Authorization (EUA) to include use of nasal swab specimens that are self-collected by individuals using the Kroger Health COVID-19 Test Home Collection Kit. This was an addition to their earlier EUA that was granted on June 1st, 2020. The testing solution combines the safety and convenience of at-home specimen collection with the expert guidance of a Kroger Health clinician through video telehealth visit.

On March 16th, Gravity Diagnostics began processing COVID-19 samples with a vision to bring increased testing to their local communities, partnering with the Commonwealth of Kentucky to serve the healthcare facilities across the state and later with Kroger Health to bring more testing to Kentucky and nationwide via drive through testing sites. This next big step with Kroger Health will allow the two organizations to make a more widespread impact for COVID-19 testing across the nation, through an innovative method focused on quality, compliance, and patient experience.

Kroger Health will make the kits available to frontline associates across Kroger's Family of Companies based on medical need first, and will expand rapidly from there, with a goal of processing up to 60,000 per week by the end of July. Gravity Diagnostics to date has processed over 250,000 COVID-19 samples. The relatively small laboratory is evolving quickly to meet the need and scale through hiring of personnel and expansion of equipment and new laboratory space.

"Everything we have done during this time is with the people of our communities and nation in mind. After partnering with Kroger Health to execute their nationwide drive throughs, we were enthusiastic to continue to expand testing through our partnership in a way that is flexible and accessible during this critical time of working to reopen the United States," said Tony Remington, CEO of Gravity Diagnostics. "We are humbled to be a part of just one of the ways Kroger Health is executing a larger vision of how the healthcare industry is evolving."

About Gravity DiagnosticsGravity Diagnostics is a full-service state-of-the-art CLIA laboratory licensed in all 50 states providing innovative laboratory testing including Infectious Disease (Upper Respiratory and Sexually Transmitted), Toxicology, and Pharmacogenomics. We are an advocate for physicians, patients, and our communities, supporting them with unsurpassed integrity, regulatory compliance, and clinical expertise. Learn more by visiting gravitydiagnostics.com.

About Kroger Health:Kroger Health, the healthcare division of The Kroger Co., is one of America's leading retail healthcare organizations, with over 2,000 pharmacies and 200 clinics in 35 states serving more than 14 million customers. Their team of 22,000 healthcare practitioners - from pharmacists and nurse practitioners, to dietitians and technicians are committed to helping people live healthier lives. They believe in practicing at the top of our licenses and enabling "food as medicine" to help prevent or manage certain diseases. Learn more atwww.krogerhealth.com.

About The Kroger Co.:At The Kroger Co. (NYSE: KR), we are Fresh for Everyone and dedicated to their Purpose: ToFeed the Human Spirit. They are, across our family of companies, nearly half a million associates who serve over 11 million customers daily through a seamless shopping experience under a variety ofbanner names. They are committed to creating #ZeroHungerZeroWaste communities by 2025. To learn more about them, visit theirnewsroomand investor relationssite.

Contact: media@gravitydiagnostics.com

Original post:
Gravity Diagnostics Partners with Kroger Health to Expand COVID-19 Testing with Home Collection Kits - News- Graphic

Covid 19 Analysis On Pharmacogenomics Market Growth in Business Future Scenarios and Brief Analysis of Top Key Players Thermo Fisher Scientific Inc.,…

The strategy analysis on Global Pharmacogenomics Market gives insights of market size, trends, share, growth, development plans, Investment Plan, cost structure, and drivers analysis. With precise data covering all key aspects of the existing market, this report offers existing data of leading manufacturers. The Pharmacogenomics market report covers marketing channels and market positioning to potential growth strategies, providing in-depth analysis for new competitors or exists competitors in the Pharmacogenomics industry. The Report Gives Detail Analysis on Market concern Like Pharmacogenomics Market share, CAGR Status, Market demand, and up to date Market Trends with key Market segments. The report provides key statistics on the market status of the Pharmacogenomics manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry. Overall, the report provides an in-depth insight of the Pharmacogenomics market covering all important parameters.

Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

Request A PDF Sample Copy Pharmacogenomics Market Report Click here: https://www.coherentmarketinsights.com/insight/request-pdf/1053

Global Pharmacogenomics market 2020-2026: Competitive Analysis

The Pharmacogenomics market report designed to provide entry support, customer profile, and M&As as well as go-to-market strategy support. We provide a detailed analysis of key players operating in the global Pharmacogenomics market, including key players such as Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Qiagen N.V., Pacific Biosciences of California, Inc., Diatech Pharmacogenetics Srl and Assurex Health Inc.

Scope of Pharmacogenomics Market:

The Pharmacogenomics market was valued at XX Million US$ in 2020 and is projected to reach XX Million US$ by 2027, at a CAGR of XX% during the forecast period. In this study, 2020 has been considered as the base year and 2020 to 2027 as the forecast period to estimate the market size for Pharmacogenomics.

Due to the pandemic, we have included a special section on the Impact of COVID 19 on the Pharmacogenomics Market which would mention How the Covid-19 is Affecting the Pharmacogenomics Industry, Market Trends and Potential Opportunities in the COVID-19 Landscape, Covid-19 Impact on Key Regions and Proposal for Pharmacogenomics Players to fight Covid-19 Impact.

The report also focuses on global major leading industry players of Global Pharmacogenomics market providing information such as company profiles, product picture, and specification, price, capacity, cost, production, revenue and contact information. Upstream raw materials and equipment and downstream demand analysis are also carried out. With tables and figures helping analyze worldwide Global Pharmacogenomics market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position. The report provides detailed information regarding the major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Pharmacogenomics market. The Pharmacogenomics Market Report analyzes opportunities in the overall Pharmacogenomics market for stakeholders by identifying the high growth segments.

The scope of the report is limited to the application of the type and distribution channel. The regions considered in the scope of the report include North America Country (United States, Canada), South America, Asia Country (China, Japan, India, Korea), Europe Country (Germany, UK, France, Italy), Other Country (Middle East, Africa, GCC). This report presents the worldwide Pharmacogenomics market size (value, production, and consumption), splits the breakdown (data status 20152019 and forecast to 2027), by manufacturers, region, type, and application.

Market segment by Type, the product can be split into:Product Type Segmentation: Epicel, IntegraIndustry Segmentation: Chemical, Cosmetic, Pharmaceutical

The Global Pharmacogenomics Market report analyses the production of goods, supply, sales, and the current status of the market in a detailed manner. Furthermore, the report examines the production shares and market product sales, as well as the capacity, production capacity, trends in sales, cost analysis, and revenue generation. Several other factors such as import/export status, industrial statistics, demand and supply ratio, gross margin, and industry chain structure have also been studied in the Global Pharmacogenomics Market report.

The report comprehends precise analytical information related to market forecasts for several upcoming years. The report also includes the particulars about the valuation of macro and microelements significant for the growth of already established Pharmacogenomics Market contenders and emerging new companies. The report uses SWOT analysis for the growth assessment of the outstanding Pharmacogenomics Market players. It also analyzes the most recent enhancements while estimating the expansion of the foremost Pharmacogenomics Market players. Additionally, the key product category and segments along with sub-segments of the global Pharmacogenomics Market are studied in the global Market research.

What Reports Provides

Full in-depth analysis of the parent market Important changes in market dynamics Segmentation details of the market Former, on-going, and projected market analysis in terms of volume and value Assessment of niche industry developments Market share analysis Key strategies of major players Emerging segments and regional markets Testimonials to companies in order to fortify their foothold in the market.

Further, in the research report, the following points are included along with an in-depth study of each point:

* Production Analysis Production is analyzed with respect to different regions, types, and applications. Here, the price analysis of various Market key players is also covered.* Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the global market. Another major aspect, price, which plays an important part in the revenue generation is also assessed in this section for the various regions.* Supply and Consumption In continuation of sales, this section studies the supply and consumption of the Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.* Other analyses Apart from the information, trade and distribution analysis for the Market, the contact information of major manufacturers, suppliers and key consumers is also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

Reasons to Buy:

* Obtain the most up to date information available on the Pharmacogenomics projects globally.* Identify growth segments and opportunities in the industry.* Facilitate decision-making on the basis of strong historical and outlook of Pharmacogenomics data.* Develop business strategies with the help of specific insights about the planned and announced Pharmacogenomics projects globally.* Keep abreast of key new-build Pharmacogenomics projects globally.* Assess your competitors planned and Pharmacogenomics projects and capacities.

Additionally, the report is joined by a vital examination of the Pharmacogenomics marketplace considering progress, part commitments, and future market forecasts. Furthermore, it offers detailed data of vendors including the profile, specifications of a product, sales, applications, annual performance in the industry, investments, acquisitions and mergers, market size, revenue, market share, and more. The report also studies individual regional market size along with country-wise and region-wise market size during the forecast period. The report also understands the export and import, production, and consumption of every particular region holding the highest market share, market size, or CAGR.

Conclusively, This report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Note: *The discount is offered on the Standard Price of the report.

Enquire here get customization & check discount, please click: https://www.coherentmarketinsights.com/insight/request-discount/1053

If you wish to find more details of the report or want a Customization Please contacts us. You can get a detailed of the entire research here.

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email: sales@coherentmarketinsights.comUnited States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

See the article here:
Covid 19 Analysis On Pharmacogenomics Market Growth in Business Future Scenarios and Brief Analysis of Top Key Players Thermo Fisher Scientific Inc.,...

What You Need to Know About COVID-19 Testing – Touro College News

When you were at Roche, you developed an automated diagnostic testing platform that is now used for COVID-19 testing. Can you explain it?

The system is based on polymerase chain reaction, PCR for short, which uses a series of temperature cycles to make multiple copies of a specific DNA or RNA sequence. Early PCR testing required lots of human intervention, which limited its use outside of research settings. The system we developed can perform the necessary steps automatically, and can process 960 samples at once, with results in eight hours. The U.S. Food and Drug Administration has approved tests that run on the system for HIV, tuberculosis and many other pathogens, and approved a test for SARS-CoV-2, the virus that causes COVID-19, in mid-March.

What is an antibody test? Should anyone get one?

Also called serological tests, these check a persons blood for antibodies to COVID-19. If a person tests positive, they have been exposed to the virus, while a negative test means they havent been exposed. Public health authorities are now trying to perform as many antibody tests as possible, which gives them an idea of the level of exposure to the virus within the population.

How reliable is COVID testing and antibody testing?

COVID-19 testslike the Roche testare used to determine if a sick person has the virus. These test a sample thats taken by swab from the back of a persons throat, and are extremely reliable, as long as the sample was taken correctly. There have been problems with the reliability of antibody testing, largely because several products reached the market without FDA review.

How can someone be sure theyre getting a reliable test?

Ask if the test has been submitted for review to the FDA, and if it has been approved by the FDA. This is indicative of the comprehensiveness of the data supporting the validity of the test.

If I test positive, does that mean Im immune?

We still dont know whether people who make antibodies to COVID-19 will be immune to infection. Even if you have a positive antibody test, you should remain vigilant with social distancing and mask use.

Do you see a vaccine in the near future?

There is tremendous effort being dedicated to vaccine development in large global pharmaceutical companies as well as in biotechnology companies. I believe we will start to see a vaccine emerge by the end of this calendar year.

You hold more than 25 patents. Of which are you most proud?

Probably the early ones that focused on identifying variation in the human genome. The early work on DNA identity has served as the foundation for the exciting field of pharmacogenomics, which explores how genes affect drug response.

What did you do before coming to Touro?

I was a senior executive in the pharmaceutical / biotechnology industry. I was also involved in several biotechnology start-ups and held an adjunct appointment at Touros New York Medical College.

Link:
What You Need to Know About COVID-19 Testing - Touro College News